SCHEMBL4597834

SCHEMBL4597834

Cc1ccc(S(=O)(=O)NC(Cc2cccc(Oc3ccc(C(=O)NO)cc3)c2)C(=O)N(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 4/20 0.51
MMP9 P14780 3/20 0.48
CTSL P07711 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
PLAU P00749 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
MMP1 P03956 2/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
HPN P05981 2/20 0.42
ST14 Q9Y5Y6 2/20 0.42
BCL2L1 Q07817 1/20 0.42
MCL1 Q07820 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HGFAC Q04756 1/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5123529 0.91 MMP13 (0.51) MMP13MMP9CTSLTDP1ITGB3
SCHEMBL4597749 0.91 TDP1 (0.54) MMP13MMP9CTSLTDP1ITGB3
SCHEMBL4598174 0.85 TDP1 (0.48) MMP13MMP9CTSLTDP1ITGB3
SCHEMBL4598594 0.84 TDP1 (0.49) MMP13MMP9CTSLTDP1ITGB3
SCHEMBL4597815 0.82 TDP1 (0.57) MMP13MMP9CTSLTDP1MMP1
SCHEMBL4598819 0.80 MMP13 (0.52) MMP13MMP9CTSLTDP1PLAU
SCHEMBL4597080 0.78 MMP13 (0.49) MMP13MMP9TDP1ITGB3MMP1
SCHEMBL14045372 0.78 MMP13 (0.49) MMP13MMP9TDP1ITGB3MMP1
SCHEMBL5125574 0.78 HDAC8 (0.49) MMP13
SCHEMBL4608941 0.76 NPSR1 (0.53) MMP13MMP9CTSLTDP1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives BEXEL PHARMACEUTICALS. INC. 2008-08-21 US claimed
EP-1906731-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES Bexel Pharmaceuticals Inc (US) 2008-04-09 EP claimed
WO-2007005603-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES BEXEL PHARMACEUTICALS, INC. (US) 2007-01-11 WO claimed
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives HGFAC, HCAR2, BCAT1 MMP13 534/4885MMP9 1292/4885CTSL 414/4885
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives HGFAC, HCAR2, BCAT1 MMP13 639/4885MMP9 1385/4885CTSL 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.